Taysha Gene Therapies (TSHA) Reports In-Line Q3 EPS

Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.09), in-line with the analyst estimate of ($0.09).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• In memo, Meta says it plans to crack down on employee token use as AI costs soar - The Information
• Abbott (ABT) Declares $0.63 Quarterly Dividend; 2.9% Yield